These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6549356)

  • 21. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil.
    Miles DW; Harris WH; Gillett CE; Smith P; Barnes DM
    Int J Cancer; 1999 Aug; 84(4):354-9. PubMed ID: 10404085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
    Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short- or long-term chemotherapy for node-positive breast cancer: LMF 6 versus 18 cycles. SAKK study 27/76.
    Jungi WF; Alberto P; Brunner KW; Mermillod B; Barrelet L; Cavalli F
    Recent Results Cancer Res; 1984; 96():175-7. PubMed ID: 6396771
    [No Abstract]   [Full Text] [Related]  

  • 24. Ludwig Breast Cancer trial LBCS III: chemo- and endocrine adjuvant treatment in postmenopausal patients.
    Gelber RD
    Recent Results Cancer Res; 1984; 96():102-9. PubMed ID: 6396763
    [No Abstract]   [Full Text] [Related]  

  • 25. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
    Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
    J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.
    Colleoni M; Price K; Castiglione-Gertsch M; Goldhirsch A; Coates A; Lindtner J; Collins J; Gelber RD; Thürlimann B; Rudenstam CM
    Eur J Cancer; 1998 Oct; 34(11):1693-700. PubMed ID: 9893654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes.
    Moliterni A; Bonadonna G; Valagussa P; Ferrari L; Zambetti M
    J Clin Oncol; 1991 Jul; 9(7):1124-30. PubMed ID: 2045854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group.
    Eiermann W; Graf E; Ataseven B; Conrad B; Hilfrich J; Massinger-Biebl H; Vescia S; Loibl S; von Minckwitz G; Schumacher M; Kaufmann M;
    Eur J Cancer; 2010 Jan; 46(1):84-94. PubMed ID: 19879750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.
    Mouridsen HT; Rose C; Brincker H; Thorpe SM; Rank F; Fischerman K; Andersen KW
    Recent Results Cancer Res; 1984; 96():117-28. PubMed ID: 6396765
    [No Abstract]   [Full Text] [Related]  

  • 30. Adjuvant oophorectomy versus CMF in premenopausal node-positive breast cancer: long-term results of an experience at the Milan Cancer Institute.
    Salvadori B; Celio L; Oriana R; Bajetta E
    Tumori; 2000; 86(3):258-9. PubMed ID: 10939610
    [No Abstract]   [Full Text] [Related]  

  • 31. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
    N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: the Southeastern Cancer Study Group experience.
    Velez-Garcia E; Moore M; Vogel CL; Marcial V; Ketcham A; Bartolucci A; Liu C; Smalley R
    Breast Cancer Res Treat; 1983; 3 Suppl():S49-60. PubMed ID: 6367861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
    Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Adjuvant mono- and polychemotherapy in breast cancer (a randomized study)].
    Semiglazov VF; Bavli IaL; Moiseenko VM; Rzhankov SV; Migmanova NSh
    Vopr Onkol; 1985; 31(12):29-35. PubMed ID: 3936272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of postoperative radiotherapy on the feasibility of optimal dose adjuvant CMF chemotherapy in stage II breast carcinoma.
    Sulkes A; Brufman G; Rizel S; Weshler Z; Biran S; Fuks Z
    Int J Radiat Oncol Biol Phys; 1983 Jan; 9(1):17-21. PubMed ID: 6687724
    [No Abstract]   [Full Text] [Related]  

  • 36. Adjuvant combination chemotherapy for operable breast cancer. Trials in progress at the Istituto Nazionale Tumori of Milan.
    Bonadonna G; Rossi A; Tancini G; Bajetta E; Marchini S; Brambilla C; Tesoro Tess JD; Valagussa P; Banfi A; Veronesi U
    Cancer Treat Rep; 1981; 65 Suppl 1():61-5. PubMed ID: 7034930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer.
    Silvestrini R; Luisi A; Zambetti M; Cipriani S; Valagussa P; Bonadonna G; Daidone MG
    Int J Cancer; 2000 Aug; 87(3):405-11. PubMed ID: 10897047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant CMF chemotherapy in operable breast cancer: ten years later.
    Bonadonna G; Rossi A; Valagussa P
    World J Surg; 1985 Oct; 9(5):707-13. PubMed ID: 3840626
    [No Abstract]   [Full Text] [Related]  

  • 39. FAC + BCG as adjuvant therapy in breast cancer: an 8-year update.
    Blumenschein GR; Buzdar AU; Hortobagyi GN
    Recent Results Cancer Res; 1984; 96():129-32. PubMed ID: 6528087
    [No Abstract]   [Full Text] [Related]  

  • 40. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
    Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
    J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.